Russia Pledges $3.9 Billion For Local Pharma Growth, As Big Pharma Scrambles To Set Up Shop
This article was originally published in PharmAsia News
Russia has called for half of all pharmaceuticals in the country to be produced domestically in the next decade, pledging to spend 122.9 billion rubles ($3.97 billion) to get international drug makers to shift drug production to the country and strengthen R&D collaboration
You may also be interested in...
The Russian government’s aggressive plan to modernize the country’s pharmaceutical industry is stimulating entrepreneurial activities, as well as a flurry of deal activity between local and foreign companies. Many uncertainties remain about the potential opportunities, however, as foreign companies try to sort out changing regulatory and business dynamics.
BIO Senior VP On International Affairs Joseph Damond On Removing Trade Barriers In Asia: An Interview With PharmAsia News (Part 2 of 2)
The former Pfizer and PhRMA exec talks about building the proper regulatory climate in emerging markets to foster innovation.
The U.S. CRO sees opportunities to align with young, domestic biopharma companies in emerging markets.